Trial Profile
A Phase I Tolerance, Safety and Efficacy Study of Alkotinib in Patients With Advanced ALK Positive /ROS1 Positive NSCLC and Previously Treated With Chemotherapy or Crizotinib
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 12 Mar 2024
Price :
$35
*
At a glance
- Drugs Alkotinib (Primary)
- Indications Non-small cell lung cancer
- Focus Adverse reactions
- Sponsors Suzhou Zelgen Biopharmaceuticals
- 04 Mar 2024 Status changed from recruiting to completed.
- 01 Mar 2023 Planned End Date changed from 31 May 2023 to 31 May 2024.
- 01 Mar 2023 Planned primary completion date changed from 28 Feb 2023 to 28 Feb 2024.